Follow-up in Early and Locally Advanced Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
A cross-sectional follow-up study of Early and Locally Advanced Breast Cancer patients after primary treatment.

Detailed Description
-----------------
The objective of this study is to assess follow-up patterns and identify patients with increased levels of physical and/or psychosocial problems after treatment in early breast cancer and locally advanced breast cancer. 830 patients stratified by cancer sites and treatment - a minimum of 120 patients within each stratum - will be recruited. Institutional data on follow-up policy, demographic and clinical data (related to treatment history and tumor characteristics) will be collected. Patients will complete a set of 139 Quality of Life questions, at one single time point. Statistical analysis includes descriptive statistic for socio-demographic and clinical data, overall and per treatment, age and risk group. Patterns of follow-up will be identified and described overall, and per treatment, age, risk group and country. Where available, normative data will be used to identify those QoL domains where there is a clinically relevant difference with the general population. Multivariable model building will be used to build predictive models on the overall population to investigate determinants for the physical, sexual and emotional needs based on the identified PROM outcomes. Factor analysis will be undertaken to investigate the inter-correlations between physical, sexual and emotional needs in the overall population and in the relevant subgroups of interest. The magnitude of the observed differences will be assessed by clinical important effect size rather than by statistical significance.

Official Title
-----------------
Follow-up in Early and Locally Advanced Breast Cancer Patients

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven Early Breast Cancer (EBC) and Locally Advanced Breast Cancer (LABC) patients who have completed their primary treatment (except endocrine therapy), between 12 months and 36 months after the diagnosis. Disease-free without any evidence of relapse Age ≥ 18 years. Ability to understand and fill out questionnaires. Written informed consent. Exclusion Criteria: Metastatic breast cancer (defined as secondary spread to other organs, such as bones, lung, liver, mediastinal lymph nodes) or DCIS. Other cancer diagnosis in the past 5 years except non-melanotic skin cancer or cervical intraepithelial neoplasia. Male breast cancer. Patients on maintenance therapy (other than endocrine therapy). Patients participating in interventional clinical studies with Quality of Life as primary endpoint. Any psychological (including preexisting psychiatric disorders), familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health-related quality of life | It will be evaluated using self-administered EORTC QLQ-C30 questionnaire | 18 months after first patient inclusion | 
| Health-related quality of life | It will be evaluated using self-administered EORTC-QLQ-BR-45 questionnaire | 18 months after first patient inclusion | 
| Health-related quality of life | It will be evaluated using self-administered EORTC OUT-PATSAT-C7 questionnaire | 18 months after first patient inclusion | 
| Health-related quality of life | It will be evaluated using self-administered EORTC Sexual Health Questionnaire | 18 months after first patient inclusion | 
| Health-related quality of life | It will be evaluated using self-administered Distress Thermometer | 18 months after first patient inclusion |